Shares of Compugen Ltd. (NASDAQ:CGEN) dropped 5.1% during mid-day trading on Wednesday . The stock traded as low as $6.78 and last traded at $6.89, with a volume of 202,151 shares changing hands. The stock had previously closed at $7.26.

CGEN has been the topic of several recent analyst reports. FBR & Co reissued a “buy” rating on shares of Compugen in a research note on Thursday, May 12th. Zacks Investment Research raised shares of Compugen from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Compugen presently has an average rating of “Buy” and an average target price of $10.25.

The company’s market cap is $349.23 million. The firm has a 50-day moving average price of $6.74 and a 200-day moving average price of $6.30.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.04. On average, analysts predict that Compugen Ltd. will post ($0.56) EPS for the current fiscal year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.